148638-76-0

Basic information

• Product Name: (S)-tert-Butyl 2-((tosyloxy)Methyl)Morpholine-4-carboxylate
• Synonyms: (S)-tert-Butyl 2-((tosyloxy)Methyl)Morpholine-4-carboxylate
• CAS NO: 148638-76-0
• Molecular Weight: 371.455
• Mol File: 148638-76-0.mol
• Article Data: 15

Chemical Properties

• CAS DataBase Reference: (S)-tert-Butyl 2-((tosyloxy)Methyl)Morpholine-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-Butyl 2-((tosyloxy)Methyl)Morpholine-4-carboxylate(148638-76-0)
• EPA Substance Registry System: (S)-tert-Butyl 2-((tosyloxy)Methyl)Morpholine-4-carboxylate(148638-76-0)

Safety Data

• Hazardous Substances Data: 148638-76-0(Hazardous Substances Data)

Usage

General Description

(S)-tert-Butyl 2-((tosyloxy)Methyl)Morpholine-4-carboxylate is a chemical compound that belongs to the class of morpholine derivatives. It is a tosylate ester, which means it contains a tosylate group (tosyloxy) attached to the molecule. (S)-tert-Butyl 2-((tosyloxy)Methyl)Morpholine-4-carboxylate is used in organic synthesis and pharmaceutical research as a potential precursor or intermediate for the synthesis of various bioactive compounds or pharmaceutical agents. The tert-butyl group in the molecule provides stability and sterically hinders certain reactions, making it a useful building block in organic chemistry. The tosylate group can also participate in various substitution reactions, making this compound versatile and valuable in synthetic chemistry.

Upstream product

• 847805-29-2 (-)-2-chloro-N-((S)-2,3-dihydroxypropyl)acetamide 
• 847805-30-5 (6S)-6-(hydroxymethyl)morpholin-3-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 132073-82-6 (S)-4-Benzyl-2-(hydroxymethyl)morpholine 
• 135065-70-2 (2R)-2-[(benzyloxy)methyl]morpholine 
• 98-59-9 p-toluenesulfonyl chloride 
• 135065-76-8 tert-butyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate 
• 135065-71-3 (R)-2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester 
• 52520-62-4 (2S)-4-benzyl-2-<<(p-tolylsulfonyl)oxy>methyl>morpholine 
• 135065-72-4 (S)-N-benzyl-3-chloroacetamidopropane-1,2-diol 
• 148638-78-2 (S)-4-Benzyl-6-hydroxymethyl-morpholin-3-one 
• 135097-68-6 tert-butyl (2R)-2-[(benzyloxy)methyl]morpholine-4-carboxylate 
• 148638-77-1 N-Benzyl-2-chloro-N-((S)-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-acetamide 
• 132073-83-7 (S)-morpholin-2-ylmethanol 

Downstream Products

• 1112179-08-4 tert-butyl (S)-2-((5-(6-((3-ethyl-4-fluoro-benzyl)carbamoyl)-2-methyl-pyrimidin-4-yl)-2H-tetrazol-2-yl)methyl)morpholine-4-carboxylate 
• 1174913-80-4 tert-butyl (2R)-2-(aminomethyl)morpholine-4-carboxylate 
• 1137478-36-4 (S)-tert-butyl 2-((2-chloro-5-(4-methoxyphenyl)pyridin-4-ylamino)methyl)morpholine-4-carboxylate 
• 1137478-31-9 (R)-tert-butyl 2-((2-chloro-5-(4-methoxyphenyl)pyridin-4-ylamino)methyl)morpholine-4-carboxylate 
• 1168103-91-0 (S)-5-((5-(4-methoxyphenyl)-4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile 
• 1137478-38-6 (R)-5-((5-(4-methoxyphenyl)-4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile 
• 1137478-37-5 (S)-tert-butyl 2-((2-(5-cyanopyrazin-2-ylamino)-5-(4-methoxyphenyl)pyridin-4-ylamino)methyl)morpholine-4-carboxylate 
• 1137478-34-2 (R)-tert-butyl 2-((2-(5-cyanopyrazin-2-ylamino)-5-(4-methoxyphenyl)pyridin-4-ylamino)methyl)morpholine-4-carboxylate 
• 167143-96-6 (S)-4-t-butoxycarbonyl-2-{2-[2-(3-methoxyphenyl)ethyl]phenoxymethyl}morpholine 
• 1489389-18-5 5-[[4-[[(2S)-morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile 

Relevant articles and documents

COMPOUNDS USEFUL FOR INHIBITING CDK7

CDK7 inhibitors according to the formula (I): wherein X is -CH(OH)CH3, -CHFCH3, -CF2CH3, or -CF3; Y is -CH=CH2 or C2H=C2H2; and Z is CH(CH3)

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Novel Triazolopyrazine Derivatives and Use Thereof

The present invention relates to novel triazolopyrazine derivatives or a pharmaceutically acceptable salt, and a pharmaceutical composition for inhibiting c-Met tyrosine kinase activity and a pharmaceutical composition for preventing or treating hyperproliferative disorders, containing the same as active ingredients. The present invention effectively inhibits c-Met tyrosine kinase activity, thereby being able to be useful as a drug for various hyperproliferative disorders such as cancers, psoriasis, rheumatoid arthritis, diabetic retinitis, etc. related to excessive cell proliferation and growth by abnormal kinase activation.